Pharma CEO: Gap between EU vision and national competencies affects health agenda

 
Despite an exceptional unity of intent during the pandemic, the revision of the bloc’s pharmaceutical legislation could suffer a bump between the EU’s vision for health and this is still conceived at the national level, Lars Fruergaard Jørgensen told EURACTIV.

Lars Fruergaard Jørgensen is CEO of Danish pharmaceutical company Novo Nordisk and the first vice-president of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

What could be the contribution of the pharmaceutical sector to the nascent European Health Data Space?

In Europe, we take personal data and privacy very seriously. When you look at the pharmaceutical companies, we have a lot of experience in conducting clinical trials, sometimes with hundreds or thousands of patients. Even large outcome trials are all made anonymous so we can still extract learnings and submit them to regulators. (...)